FDA Brief

Warning letters Drugs

FDA warning letter to

Seoul Cosmetics Co., Ltd.

High riskIssued Oct 2, 2023Posted Oct 10, 2023Center for Drug Evaluation and Research | CDER

FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.

What happened

FDA inspected the company's Incheon, South Korea drug manufacturing facility from January 30 to February 3, 2023 and found serious failures in its quality control unit, test methods, stability data, glycerin identity testing, and process validation. FDA also reviewed the company's website and product labels and found that six products were marketed as drugs without FDA approval. The company's February 21, 2023 response to the inspection findings (Form FDA 483, the list of observations given at the end of an inspection) was inadequate, and FDA placed the firm on Import Alert 66-40 on June 8, 2023.

What FDA found

  1. The quality control unit did not have the authority or resources to properly oversee manufacturing of the company's OTC drugs.

    21 CFR 211.22
  2. Test methods were not properly validated for accuracy, sensitivity, specificity, and reproducibility.

    21 CFR 211.165(e)
  3. Drug expiration dates were not supported by adequate stability data.

    21 CFR 211.166(b)
  4. Glycerin used in a drug product was not tested to confirm its identity, even though glycerin can carry dangerous DEG/EG contamination.

    21 CFR 211.84(d)(1)
  5. Manufacturing processes were not validated and equipment used to make the drugs was not properly qualified.

    21 CFR 211.100(a)
  6. Six products were sold as unapproved new drugs without an FDA-approved application and were misbranded.

    FD&C Act sections 505(a) and 502(ee), 21 U.S.C. 355(a) and 352(ee)

What FDA wants

FDA tells the company to correct the violations and respond in writing within 15 working days with what it has done and its plan to prevent recurrence, and to send DEG and EG test results for high-risk ingredients within 30 calendar days. FDA also recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • brands that buy finished OTC drug products from this contract manufacturer
  • US distributors and retailers selling imported Korean OTC drug products
  • companies sourcing glycerin-containing drug products from Korean manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk